| 摘要 |
The invention relates to the use of protein particles generated from recombinant pion protein (rPrP) subjected to a polymerisation process for the treatment and/or prevention of prion diseases. Such particles behave as an "attenuated" prion strain which is inoffensive in itself, but which can self-propagate in vivo, allowing it to compete with a conventional infectious toxic strain for the conversion of the substrate, PrPc, such that the administration of a single dose of this innocuous treatment slows down the appearance of clinical signs and the normal progression of the disease, extending the incubation period and significantly increasing survival times. Consequently, the use of the protein particles of the invention provides an effective therapeutic or prophylactic strategy against prion diseases. |
